Basic Information
| LncRNA/CircRNA Name | CTD-2589M5.4 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Cisplatin, Epirubicin | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | ovarian cancer |
| ICD-0-3 | C56.9 |
| Methods | qPCR etc. |
| Sample | cell line (A2780 and SW-6) |
| Expression Pattern | up-regulated |
| Function Description | We carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2784/PTX which is also cross resistant to the cisplatin and epirubicin. Through integrating the published data with the cisplatin resistant. |
| Pubmed ID | 29219179 |
| Year | 2018 |
| Title | Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells. |
External Links
| Links for CTD-2589M5.4 | GenBank HGNC NONCODE |
| Links for ovarian cancer | OMIM COSMIC |